Clinical Trials Browser

NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Phase 4 Active not recruiting

240 enrolled

Breast

Breast Neoplasms

NCT06625190 2026-03-11

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Phase 1/2 Recruiting

27 enrolled

CNSSarcoma

Chordoma, Myoepithelioma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Nerve Sheath Neoplasms, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT03664687 2026-02-09

REaCT-ZOL

Phase 4 Completed

211 enrolled

Breast

Breast Neoplasms

NCT06374459 2026-02-09

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Phase 1/2 Recruiting

152 enrolled

Breast

Breast Neoplasms

NCT05400603 2025-12-26

Aflac-NBL-2002

Phase 1 Recruiting

24 enrolled

CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT06759064 2025-11-19

IPIZA

Phase 1/2 Recruiting

24 enrolled

Gastrointestinal

Adenocarcinoma, Ascites, Stomach Neoplasms

NCT03173976 2025-11-06

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Phase 1 Active not recruiting

17 enrolled

Sarcoma

Chondrosarcoma

NCT02508038 2025-10-16

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Phase 1 Recruiting

22 enrolled

CNSLymphoidMyeloidOther hematologic neoplasmSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Leukemia, Myeloid, Acute, Neuroectodermal Tumors, Primitive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

REaCT-ZOL

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Aflac-NBL-2002

IPIZA

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

DiTuSarc

Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer

ETC-159-02

ZAMBONI

OS2006

METZOLIMOS

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

BonEnza

IFM-01-04

ANZAC

YAPPETIZER

HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

HOBOE

Magnolia

Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole

MOSCAR

Study on Bisphosphonates Targeting Triple-negative Breast Cancer

BLAZE

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

REaCT-BTA

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

AZABACHE

Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid

EWING2008

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NEOZOL

Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement